STAT
APRIL 5, 2024
The Centers for Disease Control and Prevention urged medical practitioners on Friday to be on the lookout for people who might have contracted H5N1 bird flu from cows. The agency also urged state health departments to rapidly assess any suspected human cases, and recommended that dairy farms with confirmed or suspected outbreaks require workers to use personal protective equipment.
PharmaVoice
APRIL 5, 2024
Infectious diseases that were “off the playing field” are now making a comeback.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
APRIL 5, 2024
News that H5N1 avian influenza has breached another mammalian species — this time dairy cows — has taken the flu science community aback. Though cows previously had been seen to be susceptible to human flu viruses , and could be experimentally infected with H5 in a lab, the absence of cow involvement until now in H5’s nearly 30-year history lulled scientists into thinking the species was outside the virus’s remit.
Pharma Times
APRIL 5, 2024
Hoxa9 and b-catenin molecules are a rare population of self-renewing HSCs found in bone marrow
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
APRIL 5, 2024
Dogs, our sunny, selfless shadows, crave little more than a daily walk, a treat or two, and their human’s happiness. But increasingly, their own happiness is the topic of concern in veterinarian offices, dog parks, and internet forums. Prozac prescriptions for dogs are on the rise, veterinarians across the country acknowledge, along with a myriad of cheaper generic mood stabilizers sold for humans but applied to pets’ separation anxiety, socialization fears, biting habits, or other
BioPharma Dive
APRIL 5, 2024
The FDA’s clearance comes three weeks after a panel of advisers endorsed expanded use of Abecma despite safety concerns raised by the agency.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Pharmaceutical Commerce
APRIL 5, 2024
In an interwith with Pharma Commerce Editor Nicholas Saraceno, Ed Schoonveld, Value and Access Advisor, Schoonveld Advisory, explains why pharmaceutical products tend to cost more in the US than the rest of the world.
STAT
APRIL 5, 2024
When Francis Collins, then-director of the National Human Genome Research Institute, testified before Congress in 2003 about the significance of sequencing the human genome that year, he introduced personalized medicine as a new concept. He predicted that in 10 years personalized medicine would allow physicians to employ “predictive genetic tests … so that each of us can learn of our individual risks for future illness and practice more effective health maintenance and disease prev
PharmaTech
APRIL 5, 2024
Zevtera has been approved to treat three types of bacterial infections and has been granted Priority Review and Fast Track and Qualified Infectious Disease Product designations.
STAT
APRIL 5, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hey! Meghana here. Today, we’re encouraging you to look elsewhere within the STAT universe for fantastic content. There’s, of course, our podcast , “The Readout Loud,” and Adam Feuerstein’s spicy new newsletter , “Adam’s Biotech Scorecard.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
pharmaphorum
APRIL 5, 2024
Our regular round-up of financings in the biotech sector is headed by rumours of a $150 to $200 million initial public offering (IPO) for Aardvark Therapeutics, an emerging player in the weight-loss category, alongside a trio of big private rounds.
STAT
APRIL 5, 2024
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still shaping up, but we expect to catch up on our reading, promenade extensively with our official mascots, and hold another listening party with Mrs. Pharmalot. The rotation will likely include this , this , this , this and this.
The Pharmacist
APRIL 5, 2024
The NHS prescription charge in England will increase to £9.90 per item as of next month, it has been announced. The 25p increase has been condemned by pharmacy leaders who are concerned about the impact on patients, especially amid the cost-of-living crisis. Amendments to the National Health Service (Charges for Drugs and Appliances) Regulations have […] The post ‘Arbitrary barrier’: Sector slams latest prescription charge rise appeared first on The Pharmacist.
STAT
APRIL 5, 2024
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week.
pharmaphorum
APRIL 5, 2024
ADRIATIC trial finds AstraZeneca's cancer immunotherapy Imfinzi improves survival in patients with limited-stage small cell lung cancer (SCLC)
European Pharmaceutical Review
APRIL 5, 2024
Interim data from a Phase I/II clinical trial suggest that mRNA-3927, an investigational mRNA therapy from Moderna, could be a promising treatment for propionic acidaemia. A 70 percent reduction in the risk of metabolic decompensation events was reported by eight participants in the 12-month pretreatment period, according to the trial results published in Nature. “We are excited to share the first published clinical data utilising an mRNA therapy for intracellular protein replacement,̶
pharmaphorum
APRIL 5, 2024
Advances in immunosuppression research may bring transplant patients closer to “one organ for life” Mike.
The Guardian - Pharmaceutical Industry
APRIL 5, 2024
Testing of 40 types of bandages found 65% had alarming levels of ‘forever chemicals’ in adhesive flaps and pads that touch wounds Many popular US bandage brands contain alarming levels of toxic PFAS “forever chemicals”, new research suggests , raising questions about the products’ safety. Testing of 40 types of bandages made by companies such as Band-Aid, Curad, Walmart and CVS found 26 products, or 65%, contain alarming levels of a marker of PFAS.
Pharma Times
APRIL 5, 2024
Affecting 80,000 people in England, 12% of brain tumour patients survive beyond five years of diagnosis
Pharmaceutical Technology
APRIL 5, 2024
MiNA Therapeutics has entered into an agreement with Nippon Shinyaku to develop RNAa therapeutics for rare neurodegenerative ailments.
pharmaphorum
APRIL 5, 2024
Germany's Merck partners Caris Discovery on artificial intelligence-powered discovery of antibody-drug conjugates in a $1.
Express Pharma
APRIL 5, 2024
Deepak Pahwa, Chairman, Pahwa Group & Managing Director, Bry-Air highlights that in order to produce superior quality products, it is imperative to provide high-quality air, devoid of even the slightest trace of moisture for various stages of pharma processes entailing manufacturing, storage, research, testing, and packaging The Indian pharma industry is poised to grow at a phenomenal rate.
Pharmafile
APRIL 5, 2024
UCB has announced that the US Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) for Bimzelx (bimekizumab-bkzx), for the treatment of adult patients with moderate to severe hidradenitis suppurativa (HS). An additional sBLA for bimekizumab-bkzx 2ml device presentations has also been accepted for review.
The Pharmacist
APRIL 5, 2024
Pharmacies should take ‘active steps’ to assess whether prescribers, including those in private clinics based outside the UK, comply with latest policy on puberty supressing hormones, the General Pharmaceutical Council (GPhC) has said. The NHS England policy, published earlier this month, sets out that puberty suppressing hormones are not available as a routine commissioning treatment […] The post GPhC: ‘Take account’ of new puberty supressing hormone policy appeared first on The Pharmacis
Pharmafile
APRIL 5, 2024
AstraZeneca has announced positive high-level results from the phase 3 ADRIATIC trial, which demonstrated that Imfinzi (durvalumab) had a statistically significant and clinically meaningful improvement in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) in patients with limited-stage small cell lung cancer (LS-SCLC) who had not progressed following concurrent chemoradiotherapy (cCRT) […] The post AstraZeneca shares results for Imfinzi in phase 3 trial
EMCrit Project
APRIL 5, 2024
The 2nd FoundStab SOP is on standard intubation. EMCrit Project by Scott Weingart, MD FCCM.
BioPharma Dive
APRIL 5, 2024
The German pharmaceutical company is “streamlining” its custom-facing teams behind Cyltezo, a copycat version of AbbVie’s immune disease drug Humira.
Pharmaceutical Business Review
APRIL 5, 2024
The deal focuses on a biosimilar candidate currently in development for the treatment of multiple oncology indications. Biosimilars are gaining recognition for their potential to offer cost-effective alternatives to existing oncology therapies, which is crucial for enhancing global oncology care. This licensing agreement is significant as it spans several key markets, including Europe and the US, marking a substantial move in mAbxience’s strategy to widen its global reach.
Pharmaceutical Commerce
APRIL 5, 2024
The latest news for pharma industry insiders.
RX Note
APRIL 5, 2024
Introduction A stretch mark (stria) is a type of scar that develops when our skin stretches or shrinks quickly. The abrupt changes cause the collagen and elastin, which support our skin, to rupture. As the skin heals, stretch marks may appear. Early stretch marks are usually red or purple due to inflammatory reaction in the skin. Over time, stretch marks lose their colour and become white or silvery in appearance (replaced by scar tissue).
Fuld & Company Blog
APRIL 5, 2024
In today’s dynamic financial landscape, boutique investment banks face the dual challenge of accelerating deal flow while simultaneously modernizing operations and scaling up to significantly increase their effectiveness. Thriving in this environment requires innovation and strategic solutions that drive lasting change. Boutique banks must focus on expanding their outreach, enhancing their execution capabilities, and securing more mandates to ensure growth.
PharmExec
APRIL 5, 2024
Abecma was found to triple progression-free survival compared to standard regimens with a 51% decline in the risk of disease progression or death in patients with relapsed or refractory multiple myeloma who were previously administered two or more lines of therapy.
pharmaphorum
APRIL 5, 2024
At Reuters Pharma USA last week in Philadelphia, Blair McNeill, SVP and head of cell therapy for Sumitomo Pharma America spoke with pharmaphorum editor-in-chief Jonah Comstock about the difficulties of collecting donations and administering an allogeneic gene therapy like RETHYMIC.
PharmExec
APRIL 5, 2024
In this Pharmaceutical Executive video interview, Currax Pharmaceuticals, CEO, George Hampton, discusses their drug Contrave and the data they have to show after a 10 years in the weight loss/obesity space.
Pharmaceutical Technology
APRIL 5, 2024
The director of BARDA’s medical countermeasures programs, Robert Johnson, talks about what the agency is planning to invest in the future.
Expert insights. Personalized for you.
363 
Let's personalize your content